{"protocolSection":{"identificationModule":{"nctId":"NCT06014541","orgStudyIdInfo":{"id":"NH00006"},"organization":{"fullName":"Ionis Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome","officialTitle":"A Prospective and Retrospective Observational/Non-interventional Study to Characterize Biomarkers and Disease Progression in Patients With MECP2 Duplication Syndrome"},"statusModule":{"statusVerifiedDate":"2025-06","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-10-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-08-09","studyFirstSubmitQcDate":"2023-08-23","studyFirstPostDateStruct":{"date":"2023-08-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-06-18","lastUpdatePostDateStruct":{"date":"2025-06-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ionis Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the study is to prospectively assess longitudinal changes in biomarkers (MECP2, potential biomarkers of target engagement and disease activity) in cerebrospinal fluid (CSF) and blood; characterize longitudinal changes in performance on clinical scales (clinician-reported measures of neurodevelopment and functioning) and caregiver-reported outcome assessments (communication, gastrointestinal, social-emotional-adaptive behavioral measures); evaluate longitudinal changes in caregiver-reported health-related quality-of-life measures; and assess the frequency, type, and severity of seizures over time.","detailedDescription":"This is a multi-center, non-randomized, non-interventional prospective and retrospective study in up to 40 participants with MECP2 duplication syndrome (MDS) who can undergo general anesthesia or conscious sedation to collect fluid biomarkers (CSF and blood), undergo electrophysiological assessments (electroencephalogram \\[EEG\\], evoked potentials \\[EP\\], pupillometry), clinical assessments and caregiver reported outcomes measures, to be used in support of the development of therapies for MDS. The study duration for each participant will be approximately 110 weeks."},"conditionsModule":{"conditions":["Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome"],"keywords":["MDS"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"OTHER"},"bioSpec":{"retention":"SAMPLES_WITH_DNA","description":"CSF and blood samples will be collected."},"enrollmentInfo":{"count":29,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MECP2 Duplication Syndrome Disease Participants","description":"Participants with a diagnosis of MDS with genetic confirmation of MECP2 duplication (or triplication) will undergo CSF and blood collection, electrophysiological and clinical assessments, up to Week 104 as a part of prospective study. Each participant's medical and family history data will be collected retrospectively from available medical notes and charts, from birth up to the end of the study (up to 110 weeks). Participants will have an option to participate in an optional sub-study that will capture pre-defined list of activities at home video."}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in MeCP2 in the CSF","timeFrame":"Baseline and on Weeks 13, 26, 39, 52"},{"measure":"Laboratory biomarkers for MECP2 Duplication","description":"Proteomic analysis of plasma samples to determine biomarkers of disease progression.","timeFrame":"Baseline and on Weeks 13, 26, 39, 52"},{"measure":"Change From Baseline in MECP2 Duplication Syndrome Severity Scale Across All Domains","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"},{"measure":"Change From Baseline in the Revised Motor Behavioral Assessment","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"},{"measure":"Change From Baseline in the Bayley Scales of Infant and Toddler Development, 3rd Edition","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"},{"measure":"Change From Baseline in Vineland Adaptive Behavior Scales 3rd Edition","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"},{"measure":"Change From Baseline in Observer Reported Communication Ability Measure","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"},{"measure":"Change From Baseline in Quality-of-Life Inventory-Disability Score","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"},{"measure":"Change From Baseline in the Frequency of Seizures","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"},{"measure":"Change From Baseline in Global Assessment of Severity of Epilepsy Scale Score","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Auditory Evoked Potential","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"},{"measure":"Change From Baseline in Visual Evoked Potentials","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"},{"measure":"Perform a retrospective chart review of the participant's medical history and family history to characterize the natural history of MDS","timeFrame":"Baseline and on Weeks 13, 26, 39, 52, 78, 104"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria\n\n* Participant has a diagnosis of MDS with genetic confirmation of MECP2 duplication (or triplication)\n* Participant has a parent or caregiver (CG) ≥ 18 years old capable of providing informed consent (signed and dated), and able to attend all scheduled study visits and provide feedback regarding the participant's symptoms and performance as described in the protocol and be able to comply with all study requirements and activities\n* Male ≥ 1 month and ≤ 65 years of age\n* No contraindications for lumbar puncture (LP)'s, blood draws, sedation (if necessary) or other study activities\n* Medically stable to complete the study and will tolerate sedation or general anesthesia and other study activities\n\nKey Exclusion Criteria\n\n* Clinically significant abnormalities in medical history (e.g., clinically significant renal, hepatic, or cardiac abnormalities; major surgery within 3 months of screening) or upon physical examination that could potentially impact the NH of MDS\n* Unwillingness or inability to comply with study procedures, including follow up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator\n* Treatment with an investigational drug, gene therapy, stem cell therapy, biological agent, or device within 30 days of screening, or 5 half-lives of investigational agent, whichever is longer (participants cannot be concurrently enrolled in NH00006 and ION440-CS1).","healthyVolunteers":false,"sex":"MALE","genderBased":true,"genderDescription":"Male participants who have a diagnosis of MDS, with genetic confirmation of MECP2 duplication (or triplication) will be enrolled.","minimumAge":"1 Month","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"],"studyPopulation":"Participants who have a diagnosis of MDS with genetic confirmation of MECP2 duplication or triplication will be enrolled into this study.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"UCSD - Rady Children's Hospital","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Gillette Children's Specialty Healthcare","city":"Saint Paul","state":"Minnesota","zip":"55101","country":"United States","geoPoint":{"lat":44.94441,"lon":-93.09327}},{"facility":"Children's Hospital of Philadelphia","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Vanderbilt University Medical Center","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Baylor College of Medicine","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D015518","term":"Rett Syndrome"}],"ancestors":[{"id":"D038901","term":"X-Linked Intellectual Disability"},{"id":"D008607","term":"Intellectual Disability"},{"id":"D019954","term":"Neurobehavioral Manifestations"},{"id":"D009461","term":"Neurologic Manifestations"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D040181","term":"Genetic Diseases, X-Linked"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D020271","term":"Heredodegenerative Disorders, Nervous System"}]}},"hasResults":false}